AlphAIalphai — Financial news for AI agents
stocktitan.netAUG 311 min read$JAZZ

Jazz Pharmaceuticals (NASDAQ: JAZZ) director to sell 1,527 shares in 2026

Jazz Pharmaceuticals (JAZZ) director Ted W. Love plans to sell 1,527 shares, valued at $373,413, on August 31, 2026, following restricted stock vesting on August 28, 2026, according to a Rule 144 notice.

Original reporting
stocktitan.net
Published Aug 31, 2026, 9:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 31, 2026, 10:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$JAZZ
Neutral
medium confidence
Mentioned
$JAZZ
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$JAZZNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to affect Jazz Pharmaceuticals' share price in the short term.

02

Market read

Primary insider sale filing; low material impact but relevant for compliance monitoring.

03

What to watch

Potential future insider sales or larger secondary offerings could increase supply later.

Relevance 4/10Novelty 4/10Timing: sale date today

Background

Form 144 filings disclose planned sales of restricted securities by insiders, providing transparency on upcoming share supply.

Company-level read

Ticker impact

$JAZZNeutralMedium confidence
Context

Director Ted W. Love filed a Form 144 to sell 1,527 shares of Jazz Pharmaceuticals on 08/31/2026.

Expected impact

Minimal impact; price likely unchanged unless broader sentiment shifts.

Evidence & confidence

The transaction size is modest relative to market cap and typical daily volume, limiting price effect.

Market effects

Sector

None significant; insider sale does not affect the broader biotech sector.

Regional

Limited to US investors tracking Jazz Pharmaceuticals.

Global

Low; no global market impact.

Counterpoint

What could challenge this read

Some traders may view any insider sell as a negative signal and short the stock.

Key entities

  • Director
    Ted W. Love

    Director of Jazz Pharmaceuticals filing Form 144 to sell restricted shares.

  • Company
    Jazz Pharmaceuticals plc

    Biopharmaceutical company listed on NASDAQ under ticker JAZZ.

Read at source← All news

Related articles

SEP 4
$JAZZHighAI 9/10

Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone?

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported that Ziihera plus chemotherapy showed a statistically significant overall survival benefit over trastuzumab in the Phase 3 HERIZON-GEA-01 trial. The study involved 914 patients across 30+ countries. The FDA approved Ziihera for first-line treatment of HER2-positive gastroesophageal adenocarcinoma, providing a commercial pathway. However, the magnitude of the survival benefit and safety concerns remain key factors for adoption.

insidermonkey.com3 min
SEP 2
$JAZZMedAI 8/10

Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?

Jazz Pharmaceuticals (JAZZ) shares fell 6.9% since its last earnings report. Q2 2026 adjusted EPS missed estimates at $5.71, but revenues rose 16% YoY to $1.21B, beating expectations. The company raised 2026 revenue guidance to $4.60-$4.75B. Xywav sales grew 13% YoY, while Xyrem sales declined 14% YoY. Oncology sales increased 32% YoY, driven by Zepzelca's 42% growth.

finance.yahoo.com2 min
SEP 2
$JAZZHighAI 8/10

Zanidatamab Plus Chemotherapy Extends OS in First-Line HER2+ Advanced GEA

Jazz Pharmaceuticals announced that zanidatamab plus chemotherapy showed improved overall survival in HER2+ advanced GEA patients compared to trastuzumab, per HERIZON-GEA-01 trial results. The HR for OS improved with longer follow-up. The FDA approved zanidatamab in August 2026 for first-line treatment, supported by earlier trial data. Jazz plans to present updated data at a medical meeting and submit findings to global health authorities.

cancernetwork.com2 min
AUG 31
$JAZZMedAI 8/10

Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why

Jazz Pharmaceuticals (JAZZ) shares rose 2.5% after positive Phase 3 trial results for Ziihera combined with chemotherapy in advanced gastroesophageal adenocarcinoma. The trial showed a statistically significant overall survival benefit, reinforcing the drug's potential. The stock closed at $250.79, up 2.6% from the previous close. JAZZ is up 44.8% year-to-date and near its 52-week high of $261.62.

financialcontent.com2 min
AUG 31
$JAZZHighAI 8/10

Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA

Jazz Pharmaceuticals (JAZZ) reported that Ziihera, combined with chemotherapy, showed statistically significant overall survival benefits in a Phase 3 trial for HER2+ advanced gastroesophageal adenocarcinoma (GEA). The results support Ziihera as a new standard of care, following its recent FDA approval. The company plans to present the data at a major medical meeting in Q4 2026.

prnewswire.com2 min